BD completes clinical trial for its wearable injector11 Feb 2020
The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.
BD (Becton, Dickinson and Company) has completed a 50-subject human clinical trial with the BD Libertas Wearable Injector.
The award-winning injector (the Good Design Award and the iF Award) is a subcutaneous drug delivery system, currently in development, that is designed to require no patient assembly and deliver biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.
The BD independently sponsored and conducted study was designed to evaluate the performance of the 5 mL BD Libertas device in human subjects, including tissue effects, skin reactivity and patient acceptance. The results are expected to be announced early 2020.
The study represents the most recent in a series of over 50 BD conducted pre-clinical and clinical studies intended to measure the performance of the BD Libertas Wearable Injector, demonstrate feasibility of 2-10 mL biologic injections into subcutaneous tissue and characterize tissue response to large volume injections in human and animal subjects.
Commenting on the study, Peter Nolan, Worldwide President, BD Pharmaceutical Systems, said: “BD is committed to bringing value to our pharma partnerships, including providing them with independent BD sponsored and generated study data to accelerate combination product development. The recent study reflects BD’s continued investment in solutions to meet pharma’s needs by expanding the design space for biologics delivery.”
HKBU scientists develop technique to eliminate drug side effects
19 May 2020
The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.Read more
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit
18 May 2020
CDMO is contracted to produce multiple clinical batches from German facilityRead more
Characterizing virus and virus-like particles
12 May 2020
New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.Read more
AI technology company launches with Novartis and Sarepta deals
11 May 2020
Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.Read more
Bio-Rad launches anti-certolizumab pegol antibodies
5 May 2020
Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.Read more
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report
13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.Read more
AstraZeneca "incredibly excited" by lung cancer treatment trial
13 Apr 2020
Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.Read more
German pharma companies are meeting the corona "stress test"
7 Apr 2020
The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.Read more
World’s leading biobanks join a global network to advance personalized healthcare research
6 Apr 2020
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.Read more
Servier strengthens its R&D pipeline with Symphogen acquisition
6 Apr 2020
Symphogen becomes the antibody center of excellence within Servier.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation